Cancer-associated blood biomarkers exist in exceedingly low concentrations within complex mixtures of high-abundance proteins such as albumin and immunoglobulins. Moreover, biomarkers in the blood may be subjected to degradation during transportation and storage. Such degradation is a significant source of bias for cancer biomarker measurement and discovery. We have created N-isopropylacrylamide porous sieving core shell """"""""smart"""""""" nanoparticles containing an internal affinity bait to perform three independent functions within minutes, in one step, in solution (serum or plasma): a) molecular size sieving with complete separation from high abundance residence proteins such as albumin and immunoglobulin, b) affinity capture of all solution phase target molecules, and c) complete protection of harvested proteins from enzymatic degradation. The captured analytes can be readily electroeluted for analysis. In our preliminary studies we have manufactured large quantities of uniform porous nanoparticles containing specific bait chemistries that bind highly labile low abundance target cancer biomarker proteins (e.g., platelet derived growth factor). We have demonstrated that the particles can capture and concentrate target proteins from serum such that the target molecule is completely removed from the bulk solution within 5 minutes, with completed exclusion of albumin and immunoglobulins. The captured proteins, even if denatured, are protected from degradation by high concentrations of proteases (trypsin or chymotrypsin) even at 37 oC overnight. The deliverable goal of this proposed feasibility R21 study is to combine this """"""""smart"""""""" nanoparticle technology with standard blood collection tubes, with or without additives/anticoagulants, to rapidly encapsulate cancer biomarkers known to be very rare and labile. The envisioned technology is a panel of dry lyophilized sub-micron sized harvesting particles that carry specific bait for known biomarkers. Following introduction of the blood or body fluid, the respective particle populations will remove all of their target molecules, in one step, in solution, from the entire volume of the sample and concentrate the sequestered analytes inside the particles. Analytes will then be eluted from the particles to yield a much higher concentration and purification compared to the starting sample. Depending on the starting volume of the blood, this technology can concentrate a biomarker many hundred fold, and prevent degradation, within minutes.

Public Health Relevance

Biomarkers for early stage cancer are urgently needed so that treatment can be initiated prior to metastasis. Unfortunately, cancer biomarkers exist in very low concentrations and are highly labile. This project will deliver a novel nanotechnology that can rapidly harvest, concentrate, and protect from degradation, labile biomarkers in whole blood or serum, in one step, in the blood collection tube.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA137706-02
Application #
7848336
Study Section
Special Emphasis Panel (ZCA1-SRRB-C (O1))
Program Officer
Rasooly, Avraham
Project Start
2009-06-01
Project End
2011-11-30
Budget Start
2010-06-01
Budget End
2011-11-30
Support Year
2
Fiscal Year
2010
Total Cost
$179,916
Indirect Cost
Name
George Mason University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
077817450
City
Fairfax
State
VA
Country
United States
Zip Code
22030
Spreafico, Filippo; Bongarzone, Italia; Pizzamiglio, Sara et al. (2017) Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget 8:46177-46190
Popova, Taissia G; Teunis, Allison; Magni, Ruben et al. (2015) Chemokine-Releasing Nanoparticles for Manipulation of the Lymph Node Microenvironment. Nanomaterials (Basel) 5:298-320
Narayanan, Aarthi; Amaya, Moushimi; Voss, Kelsey et al. (2014) Reactive oxygen species activate NF?B (p65) and p53 and induce apoptosis in RVFV infected liver cells. Virology 449:270-86
Magni, Ruben; Espina, Benjamin H; Liotta, Lance A et al. (2014) Hydrogel nanoparticle harvesting of plasma or urine for detecting low abundance proteins. J Vis Exp :e51789
Bosch, Jaume; Luchini, Alessandra; Pichini, Simona et al. (2013) Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: preliminary results. J Pharm Biomed Anal 85:194-7
Tidwell, J Lille; Liotta, Lance A (2012) Inventions and patents: a practical tutorial. Methods Mol Biol 823:391-408
Zhou, Weidong; Liotta, Lance A; Petricoin, Emanuel F (2012) The spectra count label-free quantitation in cancer proteomics. Cancer Genomics Proteomics 9:135-42
Luchini, Alessandra; Tamburro, Davide; Magni, Ruben et al. (2012) Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals. J Sports Med Doping Stud 2:
Anagostou, Anthanasia; Liotta, Lance A (2012) Small business development for molecular diagnostics. Methods Mol Biol 823:421-37
Liotta, Lance A; Petricoin 3rd, Emanuel F (2012) Regulatory approval pathways for molecular diagnostic technology. Methods Mol Biol 823:409-20

Showing the most recent 10 out of 22 publications